Tan, Eng Hooi
Robinson, Danielle E.
Jödicke, Annika M.
Mosseveld, Mees
Bødkergaard, Katrine
Reyes, Carlen
Moayyeri, Alireza
Voss, Annemarie
Marconi, Ettore
Lapi, Francesco
Reinold, Jonas
Verhamme, Katia M. C.
Pedersen, Lars
Braitmaier, Malte
de Wilde, Marcel
Ruiz, Marc Far
Aragón, María
Bosco-Levy, Pauline
Lassalle, Regis
Prieto-Alhambra, Daniel http://orcid.org/0000-0002-3950-6346
Sanchez-Santos, Maria T.
Funding for this research was provided by:
UCB Biopharma SRL and Amgen Inc requested by EMA
Article History
Received: 12 January 2023
Accepted: 19 June 2023
First Online: 12 July 2023
Declarations
:
: AM is employed by UCB Biopharma SRL. AV, JR, and MB are working at an independent, non-profit research institute, the Leibniz Institute for Prevention Research and Epidemiology – BIPS. EM and FP provided consultancies in protocol preparation for epidemiological studies and data analyses for Amgen. PBL and RL are working at an independent, non-profit research institute, the Bordeaux PharmacoEpi platform (BPE) at Bordeaux University. KV, MM, Marcel de Wilde (MW) report receiving institutional funding support from the European Medicines Agency and Innovative Medicines Initiative. KV, MM, MW have received institutional grants from Johnson and Johnson, UCB, Chiesi, GSK, and Amgen outside this work. DPA’s department has received grant/s from Amgen, Chiesi-Taylor, Lilly, Janssen, Novartis, and UCB Biopharma. His research group has received consultancy fees from Astra Zeneca and UCB Biopharma. Amgen, Astellas, Janssen, Synapse Management Partners and UCB Biopharma have funded or supported training programmes organised by DPA's department. EHT, DR, AJ, MSS, KB, CR, LP, MFR, MA have no conflicts of interest to declare.